Literature DB >> 25006881

The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma.

Christoph Roderburg1, Tom Luedde1.   

Abstract

Liver cirrhosis and hepatocellular carcinoma (HCC) represent the endstage of most chronic liver diseases and are a major global health burden. It has been consistently shown that both liver cirrhosis and HCC are triggered by inflammatory processes, but the molecular mechanisms linking chronic hepatitis with cirrhosis and HCC are only poorly understood. Recent studies suggested that the intestinal microflora as a main source of portal-vein LPS might play a critical role in this process. Here we summarize the available literature on the role of the gut microbiome in hepatofibrogenesis and -carcinogenesis. Such knowledge might help to develop novel, innovative strategies for the prevention and therapy of liver disease.

Entities:  

Keywords:  HCC; antibiotics; cirrhosis; gut microbiota; liver

Mesh:

Substances:

Year:  2014        PMID: 25006881     DOI: 10.4161/gmic.29599

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  36 in total

Review 1.  Microbiome diurnal rhythmicity and its impact on host physiology and disease risk.

Authors:  Samuel Philip Nobs; Timur Tuganbaev; Eran Elinav
Journal:  EMBO Rep       Date:  2019-03-15       Impact factor: 8.807

Review 2.  Curcumin-mediated regulation of intestinal barrier function: The mechanism underlying its beneficial effects.

Authors:  Siddhartha S Ghosh; Hongliang He; Jing Wang; Todd W Gehr; Shobha Ghosh
Journal:  Tissue Barriers       Date:  2018-02-08

3.  Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability.

Authors:  Moran Yassour; Tommi Vatanen; Heli Siljander; Anu-Maaria Hämäläinen; Taina Härkönen; Samppa J Ryhänen; Eric A Franzosa; Hera Vlamakis; Curtis Huttenhower; Dirk Gevers; Eric S Lander; Mikael Knip; Ramnik J Xavier
Journal:  Sci Transl Med       Date:  2016-06-15       Impact factor: 17.956

4.  The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?

Authors:  Eric G Meissner
Journal:  Clin Infect Dis       Date:  2018-08-31       Impact factor: 9.079

Review 5.  Contribution of the commensal microbiota to atherosclerosis and arterial thrombosis.

Authors:  Klytaimnistra Kiouptsi; Christoph Reinhardt
Journal:  Br J Pharmacol       Date:  2018-09-25       Impact factor: 8.739

Review 6.  Carcinogenesis and therapeutics: the microbiota perspective.

Authors:  Matthew C B Tsilimigras; Anthony Fodor; Christian Jobin
Journal:  Nat Microbiol       Date:  2017-02-22       Impact factor: 17.745

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Authors:  Anne Hulin; Jeanick Stocco; Mohamed Bouattour
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

8.  Lipopolysaccharide induces the differentiation of hepatic progenitor cells into myofibroblasts via activation of the Hedgehog signaling pathway.

Authors:  Xiao-Rong Pan; Ying-Ying Jing; Wen-Ting Liu; Zhi-Peng Han; Rong Li; Yang Yang; Jing-Ni Zhu; Xiao-Yong Li; Pei-Pei Li; Li-Xin Wei
Journal:  Cell Cycle       Date:  2017-05-31       Impact factor: 4.534

Review 9.  Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state.

Authors:  Zora Djuric
Journal:  Transl Res       Date:  2016-07-28       Impact factor: 7.012

10.  Elevated serum soluble CD14 levels in chronic HBV infection are significantly associated with HBV-related hepatocellular carcinoma.

Authors:  Na Li; Qianqian Zhu; Cuiling Yang; Fang Li; Zhihua Zhou; Yi Lv; Jiao Sang; Qunying Han; Zhengwen Liu
Journal:  Tumour Biol       Date:  2015-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.